HW

OIPE O	
SEP 2 4 2004	3003/
PARENTE TRADEMAN	7

PTO/SB/21 (08-03) Approved for use through 07/31/2006. OMB 0651-0031 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL	_
FORM	

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Signature

	Application Number	10/735,495
	Filing Date	12/12/2003
	First Named Inventor	Joshua D. Rabinowitz
	Art Unit	Not yet known
	Examiner Name	To be assigned
1	Attorney Docket Number	00037.08CON

ENCLOSURES (check all that apply)					
Fee Transmittal Form	Drawing(s)	After Allowance communication to Group			
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences			
Amendment / Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)			
After Final	Petition to Convert a Provisional Application	Proprietary Information			
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence	Status Letter			
Extension of Time Request	Terminal Disclaimer	Other Enclosure(s) (please identify below):			
Express Abandonment Request	Request for Refund				
Information Disclosure Statement	CD, Number of CD(s)				
Certified Copy of Priority Document(s)	Remarks				
Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 Response to Missing Parts under 37 CFR 1.52 or 1.53					
SIGNA	TURE OF APPLICANT, ATTORNEY, OR AGEI	NT			
Firm or Individual name ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303 Elaine C. Stracker, Ph.D., J.D. Telephone (650)-687-3905 Customer Number 37485					
Signature Muni	Chialo				
Date SEP. 2 4 2004					

CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the					
Typed or printed name Elaine C. Stracker SEP 2 4 2004					

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS, PO BOX 1450, ACEXANDRIA, VA 22313-1450

Elaine C. Stracker

ريخ س 2004 م

PATENT

Attorney's Docket No.: 00037.08CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/735,495

Filed:

12/12/2003

Title

DELIVERY OF ALPRAZOLAM, ESTAZOLAM, MIDAZOLAM OR

TRIAZOLAM THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

Date: SEP. 2 4 2004

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

		52001 1 01 0	
Form PTO-1449	Docket Number: 00037.08CON	Application Number: 10/735,495	
OINFORMATION DISCLOSURE CITATION ON AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.		
SEP 2 4 2004 (Use several sheets if necessary)	Filing Date: 12/12/03	Group Art Unit: Not Yet Known	
TRADEMAN OF			
PADEMI			

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et al.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	10/21/1980	4,229,447	Porter			
•	4.	04/02/1985	4,508,726	Coleman		·	
•	5.	05/13/1986	4,588,721	Mahan			
	6.	07/28/1987	4,683,231	Glassman			
	7.	09/05/1989	4,863,720	Burghart et al.			
	8.	01/23/1990	4,895,719	Radhakrishnun et al.			
	9.	09/17/1991	5,049,389	Radhakrishnun			
	10.	03/31/1992	5,099,861	Clearman et al.			
	11.	11/24/1992	5,166,202	Schweizer			
	12.	08/31/1993	5,240,922	O'Neill	1		
	13.	02/14/1995	5,388,574	Ingebrethsen	-		
	14.	10/10/1995	5,457,100	Daniel			
	15.	08/06/1996	5,543,434	Weg			
	16.	08/13/1996	5,544,646	Lloyd et al.			
	17.	08/12/1997	5,655,523	Hodson et al.	1.		
	18.	12/09/1997	5,694,919	Rubsamen et al.	1		
	19.	04/07/1998	5,735,263	Rubsamen et al.			
	20.	04/14/1998	5,738,865	Baichwal et al.			
	21.	06/02/1998	5,758,637	Ivri et al.			
	22.	06/16/1998	5,767,117	Moskowitz			
	23.	06/29/1999	5,915,378	Lloyd et al.			
	24.	08/10/1999	5,934,272	Lloyd et al.			
	25.	09/28/1999	5,957,124	Lloyd et al.		·-	
· · · · · · · · · · · · · · · · · · ·	26.	10/05/1999	5,960,792	Lloyd et al.			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92) Sheet 2 of 8 Application Number: 10/735,495 Form PTO-1449 Docket Number: 00037.08CON Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Group Art Unit: Not Yet Known Filing Date: 12/12/03 27. 11/30/1999 5,993,805 Sutton et al. 28. 6,041,777 Faithfull et al. 03/28/2000 29. 04/11/2000 6,048,857 Ellinwood, Jr. et al. 30. 04/18/2000 6,051,566 Bianco 31. 06/20/2000 Re. 36,744 Goldberg 32. 08/01/2000 6,095,153 Kessler et al. Slutsky et al. 33. 08/15/2000 6,102,036 34. 10/17/2000 6,133,327 Kimura et al. Ellinwood, Jr. et al. 35. 10/31/2000 6,140,323 36. 06/05/2001 6,241,969 Saidi et al. 6,255,334 Sands 37. 07/03/2001 01/14/2003 Horvath et al. 38. 6,506,762 39. 02/04/2003 6,514,482 Bartus et al. 40. 07/15/2003 6,591,839 Meyer et al. 09/06/2001 Staniforth et al. 41. US 2001/0020147 03/28/2002 Wilson et al. 42. US 2002/0037828 43. 05/16/2002 US 2002/0058009 Bartus et al. 44. 07/04/2002 US 2002/0086852 Cantor Schuster et al. 45. 08/22/2002 US 2002/0112723 46. 11/28/2002 US 2002/0176841 Barker et al. US 2003/0004142 01/02/2003 Prior et al. 47. 48. 02/13/2003 US2003/0032638 Kim et al. RELATED ALEXZA MOLECULAR DELIVERY CORPORATION PATENT DOCUMENTS 49. 08/04/2003 Hale et al. 10/633,876 50. 08/04/2003 10/633,877 Hale et al. 51. 12/30/2003 10/749,537 Rabinowitz et al. 52. 12/30/2003 10/749,539 Rabinowitz et al. 53. 01/27/2004 Rabinowitz et al. 10/766,149 54. 01/27/2004 10/766,279 Rabinowitz et al. DATE CONSIDERED: **EXAMINER:**

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449 Docket Number: 00037.08CON Application Number: 10/735,495 INFORMATION DISCLOSURE CITATION Joshua D. RABINOWITZ et al. Applicant: IN AN APPLICATION (Use several sheets if necessary) Group Art Unit: Not Yet Known Filing Date: 12/12/03 01/27/2004 10/766,566 Rabinowitz et al. 55. 56. 01/27/2004 10/766,574 Rabinowitz et al. 57. 01/27/2004 10/766,634 Rabinowitz et al. 58. 01/27/2004 10/766,647 Rabinowitz et al. 59. 01/28/2004 10/767,115 Rabinowitz et al. 60. 01/29/2004 Rabinowitz et al. 10/768,205 Rabinowitz et al. 61. 01/29/2004 10/768,220 62. 01/29/2004 10/768,281 Rabinowitz et al. 63. 01/29/2004 10/768,293 Rabinowitz et al. 64. 01/30/2004 10/769,046 Rabinowitz et al. 65. 01/30/2004 10/769,051 Rabinowitz et al. 66. 01/29/2004 10/769,157 Rabinowitz et al. 67. 01/29/2004 10/769,197 Rabinowitz et al. 68. 02/09/2004 10/775,583 Rabinowitz et al. 69. 02/09/2004 10/775,586 Rabinowitz et al. 70. 03/03/2004 10/791,915 Hale et al. 71. 03/03/2004 Rabinowitz et al. 10/792,001 72. 03/03/2004 10/792,012 Hale et al. 73. Rabinowitz et al. 03/03/2004 10/792,013 74. 03/03/2004 10/792,096 Hale et al. 75. 03/03/2004 10/792,239 Hale et al. 76. 03/31/2004 Rabinowitz et al. 10/813,721 77. 03/31/2004 Rabinowitz et al. 10/813,722 78. 03/31/2004 10/814,690 Rabinowitz et al. 79. 03/31/2004 10/814,998 Rabinowitz et al. 80. 04/01/2004 Rabinowitz et al. 10/815,527 81. 04/01/2004 10/816,407 Rabinowitz et al. 82. 04/01/2004 Rabinowitz et al. 10/816,492 83. 04/01/2004 10/816,567 Rabinowitz et al. 84. 08/04/2004 10/912,462 Hale et al. **EXAMINER:** DATE CONSIDERED: EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Application Number: 10/735,495 Form PTO-1449 Docket Number: 00037.08CON INFORMATION DISCLOSURE CITATION Joshua D. RABINOWITZ et al. Applicant: IN AN APPLICATION (Use several sheets if necessary) Filing Date: 12/12/03 Group Art Unit: Not Yet Known 85. 01/23/2003 US 2003/0015196 Hodges et al. 86. 04/03/2003 US 2003/0062042 Wensley et al. 87. US 2003/0209240 Hale et al. 11/13/2003 88. 01/02/2003 US 2003/0000518 Rabinowitz et al. 89. 01/09/2003 US 2003/0005924 Rabinowitz et al. 90. 01/09/2003 US 2003/0005925 Hale et al. 91. 01/09/2003 US 2003/0007933 Rabinowitz et al. Rabinowitz et al. 92. 01/09/2003 US 2003/0007934 93. 01/16/2003 US 2003/0012737 Rabinowitz et al. 94. US 2003/0012738 Rabinowitz et al. 01/16/2003 95. 1/16/2003 US 2003/0012740 Rabinowitz et al. 96. 01/23/2003 US 2003/0015189 Rabinowitz et al. 97. 01/23/2003 US 2003/0015190 Rabinowitz et al. 98. 01/23/2003 US 2003/0017114 Rabinowitz et al. 99. 01/23/2003 US 2003/0017115 Rabinowitz et al. 01/23/2003 US 2003/0017116 100. Rabinowitz et al. 101. 01/23/2003 US 2003/0017117 Rabinowitz et al. 102. 01/23/2003 US 2003/0017118 Rabinowitz et al. 103. 01/23/2003 US 2003/0017119 Rabinowitz et al. 01/23/2003 Rabinowitz et al. 104. US 2003/0017120 105. 1/30/2003 US 2003/0021753 Rabinowitz et al. 106. 01/30/2003 US 2003/0021754 Rabinowitz et al. 107. 01/30/2003 US 2003/0021755 Hale et al. 108. 02/20/2003 US 2003/0035776 Hodges et al. 109. 05/15/2003 US 2003/0091511 Rabinowitz et al. 110. 05/27/2004 US 2004/010148 Hale et al. 111. 07/31/2003 Rabinowitz US 2003/0138382 11/06/2003 US 2003/0206869 Rabinowitz et al. 112. 113. 01/15/2004 US 2004/0009128 Rabinowitz et al. 114. 05/20/2004 US 2004/0096402 Hodges et al. DATE CONSIDERED: **EXAMINER:** EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in

conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 5 of 8 Application Number: 10/735,495 Docket Number: 00037.08CON Form PTO-1449 Joshua D. RABINOWITZ et al. INFORMATION DISCLOSURE CITATION Applicant: IN AN APPLICATION (Use several sheets if necessary) Group Art Unit: Not Yet Known Filing Date: 12/12/03 115. 05/27/2004 US 2004/0099269 Hale et al. 06/03/2004 US 2004/0105818 Hale et al. 116. 117. 06/03/2004 US 2004/0105819 Hale et al. 07/01/2004 US 2004/0126326 Rabinowitz et al. 118. Rabinowitz et al. 119. 07/01/2004 US 2004/0126327 120. 07/01/2004 US 2004/0126328 Rabinowitz et al. 07/01/2004 US 2004/0126329 Rabinowitz et al. 121. US 2004/0127481 122. 07/01/2004 Rabinowitz et al. 123. 08/12/2004 US 2004/0156788 Rabinowitz et al. 124. 08/12/2004 US 2004/0156789 Rabinowitz et al. 125. 8/12/2004 US 2004/0156790 Rabinowitz et al. Rabinowitz et al. 126. 08/12/2004 US 2004/0156791

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
-	127.	01/02/1996	CA 2,152,684	Canada			
,	128.	03/14/1990	EP 0 358 114	Europe			
	129.	07/03/2001	EP 1 080 720	Europe			•
	130.	08/29/2001	EP 0 606 486	Europe			
	131.	03/22/1990	WO 90/02737	WIPO			
	132.	04/11/1996	WO 96/09846	WIPO			
	133.	05/09/1996	WO 96/13161	WIPO			
	134.	05/09/1996	WO 96/13290	WIPO	j .		
	135.	05/09/1996	WO 96/13291	WIPO			
	136.	05/09/1996	WO 96/13292	WIPO			
	137.	10/03/1996	WO 96/30068	WIPO			
	138.	08/07/1997	WO 97/27804	WIPO			

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Form PTO-1449				Docket Number: 00037.08CON	Application Number: 10/735,495	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION				Applicant: Joshua D. RABINOWITZ et al.		
(Use several sheets if necessary)			essary)	Filing Date: 12/12/03	Group Art Unit: Not Yet Known	
	139.	05/28/1998	WO 98/22170	WIPO		
·	140.	07/23/1998	WO 98/31346	WIPO		
	141.	08/27/1998	WO 98/36651	WIPO		
	142.	04/08/1999	WO 99/16419	WIPO		
	143.	12/16/1999	WO 99/64094	WIPO		
	144.	01/06/2000	WO 00/00176	WIPO		
	145.	01/06/2000	WO 00/00215	WIPO		
	146.	05/18/2000	WO 00/27363	WIPO		
	147.	05/25/2000	WO 00/29053	WIPO		
	148.	09/17/2000	WO 00/47203	WIPO		
	149.	11/02/2000	WO 00/64940	WIPO		
	150.	11/09/2000	WO 00/66084	WIPO		
	151.	11/09/2000	WO 00/66206	WIPO		
	152.	12/21/2000	WO 00/76673	WIPO		
	153.	01/25/2001	WO 01/05459	WIPO		
	154.	03/28/2002	WO 02/24158	WIPO		
	155.	03/28/2002	WO 02/24158	WIPO		
	•					
	•	OTHE	R DOCUMENTS	(including author, title, Date, P	ertinent Pages, Etc.)	
Examiner Initials	Ref. No.	Title			•	
	156.		t al. (1981). "Patient-Co ! Surg. 195(6):700-705.		Concept of Postoperative Pain	
	157.		t al. (1990), "Cocaine-bopharmacology (Berl).		eys: reinforcing and physiological	
	158.		Byron, P. (1986). "Depe		ption Kinetics on Aerosol Particle	
<u> </u>	159.	Darquenne, C. et al. (1997). "Aerosol Dispersion in Human Lung: Comparison Between Numerical Simulations and Experiments for Bolus Tests," American Physiological Society. 966-974.				
	160.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," <i>Journal of Applied Physiology</i> . 32(5):591-600.				
EXAMI	NER:			DATE CONSIDERED:		
				on conforms with MPEP 609. Dravext communication to applicant.	w a line through the citation if not in	
PTO/SB/ 08 (2-92)		· · · · · · · · · · · · · · · · · · ·	Patent and Trademark Office	e. U.S. DEPARTMENT OF COMMERCE	

Form PTO-1449		Docket Number: 00037.08CON	Application Number: 10/735,495	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Joshua D. RABINOWITZ et al.		
(L	Use several sheets if necessary)	Filing Date: 12/12/03	Group Art Unit: Not Yet Known	
161.	Dershwitz, M., M.D., et al. (Septembe versus Intravenous Morphine in Health			
162.	Finlay, W.H. (2001). "The Mechanics Diego Formula 2.39. pp.3-14 (Table o		sols", Academic Press: San	
163.	Gonda,I. (1991). "Particle Deposition Scientific Foundations. Crystal R.G. at 2294.			
164.	Hatsukami D, et al. (May 1990) "A me humans." Pharmacology Biochemistry		es of smoked cocaine-base to	
165.	Heyder, J. et al. (1986). "Deposition of 0.005-15 μm," J. Aerosol Sci. 17(5):81		itory Tract in the Size Range	
166.	Huizer, H., "Analytical studies on illic Pharmaceutisch Weekblad Scientific E		ation during heroin smoking."	
167.		PhD, (October 1998). "Prying Open the Door to the Tobacco e Minnesota Tobacco Trial," <i>JAMA</i> 280(13):1173-1181.		
168.	Lichtman, A.H. et al. (1996). "Inhalati in Mice," Journal of Pharmacology and			
169.	169. Martin, B.R. and Lue, L.P. (May/June 1989). "Pyrolysis and Volatilization of Cocaine Analytical Toxicology 13:158-162.			
170	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.). "Smoked heroin self-administr	ation in rhesus monkeys,"	
171.	McCORMICK, A.S.M., et al., "Bronch BRITISH JOURNAL OF ANAESTHI			
172.	Meng, Y. et al. "Inhalation Studies Wi 173:201-224.	ith Drugs of Abuse, "NIDA Rese	earch Monograph, (1997)	
173.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," <i>Drug and Alcoho</i>		e and other stimulants via	
174.	Office Action mailed 8/13/2003 for US BENZODIAZEPINES THROUGH	S application 10/153,313 filed 05 I AN INHALATION ROUTE	5/21/2002 "DELIVERY OF 3"	
175.		sion of Nicotine in Tobacco Smoke to Its Volatile and Available of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.		
176. Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco pp. 1-8.				
177.	Seeman, J. et al. (1999). "The Form of Nicotine Acid Salts to Nicotine in the			
EXAMINER:		DATE CONSIDERED:		
	tial if citation considered, whether or not the citation to considered. Include a copy of this form with n		line through the citation if not in	

PTO/SB/08 (2-92) Sheet 8 of 8

Form PTO-1449		Docket Number: 00037.08CON	Application Number: 10/735,495
	ION DISCLOSURE CITATION I AN APPLICATION	Applicant: Joshua D. RABINOWITZ et al.	
	Use several sheets if necessary)	Filing Date: 12/12/03	Group Art Unit: Not Yet Known
1.50	10.1: TV 12.1.1 TV (10.07) ((41	· · · · · · · · · · · · · · · · · · ·
178.	Sekine, H. and Nakahara, Y. (1987). Inhalation Efficiency and Pyrolysis Pt 32(5):1271-1280.		
179.	Vapotronics, Inc. (1998) located at htt June 5, 2000).	tp://www.vapotronics.com.au/ba	nner.htm., 11 pages, (visited on
180.	Ward, M.E. MD, et al. (December 199) Administration from a Novel Aerosol 62(6):596-609.	77). "Morphine Pharmacokinetic Delivery System," Clinical Pha	s after Pulmonary armacology & Therapeutics
181.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and Do Biochemistry & Behavior. 55(2):237-	emonstration of Their Biological	Cocaine Base and Its Activity." Pharmacology
	·		
EXAMINER:		DATE CONSIDERED:	

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.